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Proteomics has led to the discovery of several biomarkers within an individual’s bloodstream 
that can be used in the diagnostic process for disease. Identification of novel biomarkers have a 
significant impact in the area of public health, with the potential to replace existing diagnostic 
methods that are complicated, costly, and that pose considerable risk to the patient. Cardiac 
catheterization, the current diagnostic method for coronary artery disease, is such an invasive 
procedure. An over-abundance of negative test results leads to the inquiry whether exposing all 
symptomatic patients to the procedure is in a physician’s best interest.  
A statistical analysis involving multivariate logistic regression and evaluation of 
predictive models identified a panel of biomarkers that can be used to classify patient with 
coronary artery disease and those with “normal” coronary arteries. This panel was used in 
conjunction with common clinical risk factors for heart disease to examine the added predictive 
power of the multi-marker panel when combined with clinical characteristics.  
A four-marker panel consisting of OPN, IL1β, Apo-B100, and Fibrinogen were found to 
be statistically significant predictors of coronary artery disease in a predictive logistic model 
adjusting for clinical risk factors, diabetes status and smoking status. The ability to identify 
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patients that did not have clinically relevant coronary disease based on currently used clinical 
risk factors increased greatly, from zero to approximately thirty percent of the patients, with the 
inclusion of the biomarker panel. 
The use of a blood screening test for the diagnosis of coronary artery disease among 
symptomatic patients can limit the number of unnecessary cardiac catheterizations, reducing 
healthcare costs and patient risks associated with the invasive nature of the procedure. However, 
with such a test, there may be some discrimination error present, and the cost of misdiagnosing a 
patient with clinically relevant coronary artery disease needs to be weighed against the benefits 
of the test. 
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1.0  INTRODUCTION 
Biological markers, more commonly referred to as “biomarkers,” refer to observable 
measurements derived from a patient that can be used to describe certain biological 
developments, including disease status, risk, or prognosis for that patient. According to an NIH 
working group, the definition of a biomarker is standardized to be “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention [1]. These biomarkers can be 
classified into separate categories based on their clinical properties. For the purpose of this paper, 
the term biomarkers will be used to denote biological components that indicate disease status of 
an individual; they are disease biomarkers consisting of diagnostic properties. More specifically, 
this paper is interested in circulating biomarkers ascertained from advanced proteomics methods.  
Previously, biomarkers were commonly found to be simple physiological measurements, 
such as one’s blood pressure or heart rate, but have now evolved into complex imaging 
techniques and multi-marker genomic/proteomic panels [2]. This revolution allows researchers 
to interrogate blood and serum samples for potential markers that may not correspond with a 
patient’s sense of well-being, but are evidently affecting the disease status of an individual. This 
method of diagnosis is especially attractive in areas where the incidence of disease is high and 
current diagnostic methods are both costly and invasive in nature.  
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Novel discoveries in biomarker research have a significant impact in the area of public 
health, providing alternative diagnostic methods for currently used invasive procedures, thus 
reducing the existing medical complications and economic burden of such procedures. 
1.1 CORONARY ARTERY DISEASE 
The application of biomarker research related to coronary artery disease (CAD) is the primary 
focus of this thesis. In the United States, CAD is the leading cause of mortality, accounting for 
about one of every six deaths. In 2009, 386,324 deaths due to CAD were recorded [3]. The 
disease occurs when the coronary arteries harden and narrow, due to atherosclerosis, preventing 
oxygen from reaching the heart. The most common symptom of coronary artery disease is 
angina, or chest pain, but a patient may also experience fatigue, light-headedness, or shortness of 
breath. However, sometimes an individual will experience myocardial infarction (a heart attack) 
or immediate death without having any of the previous symptoms. The use of screening 
procedures allows for early detection of the disease so successful interventions can be performed 
to reduce chances of infarct or death.  
The current diagnostic method for CAD involves invasive coronary angiography, where 
medical imaging is used to detect a dye injected into the arteries by way of cardiac 
catheterization. This involves the insertion of a catheter, a thin and flexible tube, through a 
brachial or femoral artery and up to the aorta and chamber of the heart, where the dye is then 
released into the bloodstream [4]. Coronary angiography has been a highly efficient screening 
procedure for the detection of coronary stenosis and is regarded as the current gold standard for 
determining clinically significant CAD among symptomatic patients, but complications arising 
3 
from the procedure have been criticized [5]. Several common complications include arrhythmias 
(mostly attributed to anxiety about the procedure), bleeding and hematoma around the femoral 
artery region, allergic reactions to the injected dye, and anesthetic complications [6, 7]. 
Furthermore, a patient undergoing the catheterization procedure is exposed to localized x-ray 
radiation for an extended period of time, increasing the risk of cancer and other genetic effects 
[8].  
The alarming rate of CAD has led to an increase in the number of cardiac catheterizations 
performed in hospitals, thus increasing the incidence of these complications. Almost half of the 
patients referred for catheterizations are found to have insignificant coronary lesions, and are 
unnecessarily exposed to procedural complications [9]. One alternative to the invasive procedure 
would include the identification of biomarkers existing in a patient’s bloodstream. Biomarker 
discovery regarding CAD would reveal a safer, more pragmatic diagnostic procedure than 
coronary angiography with cardiac catheterization.   
1.1.1 Symptomatic Patients 
Patients referred for catheterization come in to the emergency room (ER) or heart clinic showing 
symptoms of CAD.  This cohort of patients excludes those that have experienced a cardiac event, 
such as myocardial infarction, who skip the ER and are immediately sent for percutaneous 
intervention. For the patients received in the ER or heart clinic, an assessment of the individual is 
performed to determine the pretest probability of having CAD [10]. This may include looking at 
a patient’s medical history and existing clinical characteristics (obesity, smoking, age, etc.). If 
the pretest probability for CAD is low to intermediate, a non-invasive stress test and/or  
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Figure 1. Patient experience during the diagnostic process of coronary artery disease 
 
electrocardiogram (EKG) may also be taken into consideration to determine the likelihood of 
disease. Following the conclusion of an insignificant pretest probability, the patient may be 
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treated for his or her symptoms and sent home, being reassured there is insignificant evidence of 
disease. If the pretest probability and likelihood for CAD is high, a patient will be sent for 
catheterization to view any blockages in the arteries and determine the significance of CAD. 
Figure 1 demonstrates the patient flow from experiencing symptoms to diagnosis. 
1.1.2 Biomarkers and Coronary Artery Disease 
Cardiovascular disease is often accompanied with sources of inflammation and plaque 
instability, followed by thrombosis within the arterial regions of the heart. Resulting ischemia 
may be followed by remodeling of the heart’s ventricles. Investigation into the biological 
pathways for atherosclerosis involving inflammation, plaque instability, thrombosis, and 
remodeling of the extracellular matrix, has identified several biomarkers associated with acute 
coronary syndromes [11]. An up-regulation of proteins responding to these biological processes 
can provide useful diagnostic information for cardiac complications. For example, troponin is 
widely one of the most popular biomarkers for heart disease, where elevated levels of this protein 
points to the extent of injury to the heart during myocardial infarction [12]. However, there has 
been less success in regards to the clinical application of biomarkers to determine the degree of 
coronary artery disease among symptomatic patients. One suggestion is that a combination of 
protein changes in serum can address the severity of disease better than previous attempts that 
have focused on single markers [13-15]. Previous research has supported moderate improvement 
in risk models of coronary disease by implementing multiple biomarkers among other 
populations [16]. Adaptation of this multi-marker approach may point to a specific set of 
markers that would improve risk assessment among symptomatic patients, as defined by this 
paper. 
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Identifying biomarkers in serum of symptomatic patients could lead to the development 
of a clinical assay to use as a diagnostic method for those patients with a high pretest probability 
and likelihood for CAD. Instead of referring patients for catheterization based on a clinical 
assessment, stress test, and/or EKG, a less costly blood assay can be performed to filter out 
symptomatic patients that would otherwise be diagnosed negative for CAD. Data from a clinical 
study is analyzed later in this paper to demonstrate the effectiveness of using serum protein 
profiles and clinical characteristics as biomarkers for clinically relevant CAD. 
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2.0  LITERATURE REVIEW 
Several methods for assessing biomarkers are currently used, and there is some debate in the best 
way to measure the predictive power of new biomarkers. Logistic regression is a common 
classification technique that is generally employed for problems involving biomarkers, while 
receiver operating characteristic (ROC) curves have been used to evaluate the predictive ability 
of these new biomarkers. In this literature review, these common statistical methods for 
classification of disease and the evaluation of biomarkers are covered. 
2.1 STATISTICAL METHODS FOR PREDICTION 
2.1.1 Odds ratios 
Before delving into any of the more advanced statistical methods, it is important to grasp the 
concept of the odds ratio and how it used in clinical interpretation. In biomarker experiments, it 
is often desired to know the probability of an event, or the probability a patient is diagnosed with 
disease. Odds can then be defined as the ratio of the probability the event will occur versus the 
probability the event cannot occur [17].  In terms of patients who are symptomatic for coronary 
artery disease: 
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If p then equals the probability of disease for a patient, 1-p would equal the probability 
the patient does not have disease and the above equation can be reformulated as 
      
 
   
 
For example, if a clinical test using biomarkers determined a patient to have a 60% risk 
of CAD, the odds this patient actually has the disease would be 60% / 40%, or 1.5. This means 
the patient is 50% more likely to be diagnosed with disease than disease-free by a gold standard 
assessment, i.e. coronary angiography. If the odds of disease equal 1, this means the patient has 
the same chance of being diagnosed positive or negative, and odds less than 1 means the patient 
has a lesser chance to be diagnosed with disease according to the angiographic test. 
The odds ratio compares the odds of an event occurring between two patients:  
            
  
    
  
    
⁄  
If the odds of CAD for patient one was 1.5, and the odds of disease for patient two was 
1.2, the odds ratio would then be 1.5 / 1.2, or 1.25. This means patient 1 has a 25% higher chance 
of having a positive result from coronary angiography than patient 2. This concept of odds ratios 
is carried over for logistic regression, and it will be shown how predicted probabilities of disease 
for patients can be derived from odds ratios. 
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2.1.2 Binary Logistic Regression 
Binary logistic regression is a common statistical method for predicting the classification of 
subjects according to a dichotomous outcome. Many times, in health sciences, the goal is to 
differentiate those with and without a specific disease. Logistic regression has the ability to 
model the probability of disease, or any categorical outcome, and how the addition or subtraction 
of predictor variables affects that probability [18]. As opposed to linear regression methods, the 
logistic regression model estimates a linear function based on the log-odds of disease. This is 
because the relationship between the probability of the outcome and its predictors is usually 
nonlinear [19]. A unit increase in the predictor will have less of an impact when the probability 
of disease is close to 0 or 1, forming a logistic function, demonstrated by figure 2. Where  ̂ 
equals the probability of disease and β0 and β represent numerical coefficients, the analytical 
form of this logit function is 
 ̂  
        
   
             
 
.  The regression model can then be written out as 
  (
 ̂
   ̂
)        
   
Notice that the left side of the equation is the natural log of odds equation specified in 
section 2.1.1. Exponentiation both sides of the regression model then gives odds ratio estimates 
for the β’s. With some simple algebra, the regression model can then be remodeled to match the 
logit function to calculate the estimated probability of disease. 
Coefficients for main effects in the logistic regression model are generated through 
maximum likelihood estimators (MLE). Simply put, the MLE is an estimate for a parameter that 
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maximizes the probability of the outcome, or maximizing the agreement between observed data 
and expected values from the model [19]. Therefore, coefficients in a logistic regression model 
for coronary artery disease would be derived so that the most probable set of predictions can be 
made for the observed data. Statistical software can be used to easily compute these values when 
fitting a predictive model. 
How well a model fits the data is determined by the deviance of the model. A simple way 
to describe deviance is the difference between the observed values and the expected values from 
the logistic model. The general idea would be to fit a model with a set of predictors that produces 
the lowest deviance, indicating a closer fit to the model [19]. 
 
Figure 2. Graphical form of a logit function  
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Graph of the logit function
11 
When combining several markers for prediction, which is becoming more and more 
popular with proteomic and genomic technologies, logistic regression serves as a useful tool for 
finding the best set of markers to use as a diagnostic tool [20]. However, using multiple signature 
of biomarkers for diagnostic tests leads to more difficulties in selecting the most predictive set of 
markers from a large list of candidates [21]. A simple approach to the variable selection process 
to obtain the most parsimonious model is forward stepwise selection, where variables are entered 
into the final model based on statistically significant relationships with the outcome. This differs 
from standard forward selection because variables that have entered the model in the stepwise 
method will also have potential to exit the model, based on the statistical significance of their 
relationship with the outcome once new predictors are added. 
As previously discussed, the main assumption of logistic regression is that predictors 
within the model hold a linear relationship with the log-odds of the outcome. This is usually 
straightforward when dealing with categorical or ordinal predictors, but presents some 
difficulties when predictors are in a continuous form. 
2.1.3 Continuous and Categorical Predictors 
Protein biomarkers are usually reported on a continuous scale to reflect the concentration of the 
protein in a subject’s serum. While the assumption of normality does not necessarily need to hold 
for variables used in logistic regression, if a predictor is normally distributed for both levels of 
the outcome, the logistic regression model will be better at describing a linear relationship 
between the predictor and the outcome [19]. However, most biomarkers have heavily skewed 
distributions and do not meet the assumptions of normality. For these variables, a log 
transformation to the data generally approximates a normal distribution [20]. More importantly, 
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proteins measured on the log-scale will produce more interpretable odds ratios than if they were 
left in their original scale. Figure 3 shows histograms of the frequency distributions of 
osteopontin (OPN) concentrations among 239 patients enrolled in a cohort study. It is seen that a 
natural logarithm transformation applied to the data (right), gives a much better approximation to 
the normal curve than the regular, skewed data (left).  
 
Figure 3. Histograms of the distribution of OPN and ln(OPN) 
OPN on the original scale (left) has a heavily skewed right distribution. A natural  



































 If the log-linear assumption of logistic regression is violated, the predictive model will 
produce inaccurate estimates for the odds-ratios. Dichotomization or categorization of 
continuous predictors is commonly used in exploratory stages to fit logistic regression models 
when the linear relationship is questionable [22].  
 Categorization of variables into two or more categories is often done in medical research 
as a way to simplify the interpretation of odds ratios, creating regression models with step 
functions. Factoring by tertiles, quartiles, or quintiles is commonly seen in proteomic analysis 
when clinically relevant thresholds are not available [20]. This crude approach to categorization 
can be used to identify a log-linear relationship between the outcome and its predictor.  
Moving forward with the factored continuous variables may present complications for 
clinical interpretation. First, the cutpoints used to factor continuous variables need to be 
explicitly defined when translating results into other research. Second, categorization of these 
variables discards information that may be relevant to the analysis. It is improbable that a 
subject’s risk for disease will suddenly increase when one of the thresholds is crossed. If a linear 
assumption is validated, continuous variables will provide more powerful statistical results than 
their factored counterparts. Therefore, categorization of continuous variables is valid in an 
exploratory process, but final analysis should be conducted on the continuous form of the data. If 
the data is truly expected to be non-linear with respect to the log-odds of the outcome, some 
more advanced modeling techniques can be used to address the situations.  
2.1.3.1 Fractional Polynomials 
The idea of fractional polynomials in regression is discussed in detail by Royston and Altman 
[23]. Fractional polynomials are used to transform continuous data to investigate improvements 
in model fit, compared to the straight line model        , or in other words, the model without 
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a transformation applied to the covariate x [24]. Transformations are usually applied to 
continuous covariates in the event there is a nonlinear relationship with the dependent variable, 
in order to obtain better estimates for model coefficients. In regular polynomial regression, the 






, etc.) to describe a nonlinear 
relationship it may have with the dependent variable (in the case of logistic regression, this 
would be the log-odds). The fractional polynomial method extends the current theory of 
polynomial regression by including negative and fractional powers for the covariates, usually 
from the set -2, -1, -0.5, 0, 0.5, 1, 2, 3 [22]. In this sequence of powers, 0 refers to a natural log 
transformation. Deviance of the model with the nonlinear transformation is compared to the 
deviance of the model without the transformation, and this difference is formally tested to 
determine whether or not the transformation should be used [23]. Using one of these fractional 
polynomial transformations can be referred to as first-degree polynomials. 
 Fitting a main effect with first-degree polynomials may not provide enough flexibility to 
fit a model, and in such cases, second-degree polynomials can be explored [24]. If p is a first-
degree fractional polynomial, a regression model with the nonlinear transformation can be 
written:       
 . Where q is a second-degree fractional polynomial, the equation featuring the 
transformations would be written:       
     
 . Both p and q are chosen from the same set 
of values, -2, -1, -0.5, 0, 0.5, 1, 2, 3 and all possible combinations of first and second degree 
polynomials are explored to provide the model fit. 
 Fractional polynomials provide a flexible and more practical approach to modeling 
continuous covariates in an appropriate functional form, as opposed to categorization of these 
covariates which may present several disadvantages and statistically significant loss of 
information. Provided a nonlinear relationship exists between the dependent and independent 
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variables, fitting a logistic regression model with fractional polynomials will produce more 
accurate odds-ratios for covariates within the model.  
2.2 EVALUATION OF BIOMARKERS 
One of the main uses of biomarkers is to make a diagnosis more reliable, more rapidly, and 
inexpensive compared to existing methods [25]. However, proper evaluation of a biomarker 
needs to be assessed before it can be determined useful. Clinicians looking to implement 
biomarkers into their clinical practice are most concerned with diagnostic accuracy. Diagnostic 
accuracy refers to the ability of a biomarker to classify subjects into clinically relevant groups 
and is the general purpose of biomarker analyses [26]. That is, can a biomarker accurately 
distinguish between those patients that truly do have a disease and those that in fact do not have 
the disease? Several statistical tools can be used to measure diagnostic accuracy to determine if it 
should be used in clinical practice. 
2.2.1 Multiple Comparisons 
Valid biomarkers should have a greater presence in the affected individuals than the unaffected 
individuals. [27]. Statistical comparative tests such as the Student’s t-test or Wilcoxon rank-sum 
test are commonly used to detect statistically significant differences in biomarker concentrations 
among disease categories. In most research studies, multiple biomarkers are assessed from a 
sample, creating inflation in type I errors. The Bonferroni adjustment for p-values is a common 
method to use for multiple comparisons, but when the number of comparisons is large, this 
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method can be too conservative. Letting k equal the number of comparisons and α equal the 
selected type I error rate, the Bonferroni method adjusts the error rate by α/k. For large values of 
k, the adjustment becomes radically small, reducing the chance that any hypothesis be rejected. 
Controlling for the false discovery rate (FDR) using a method proposed by Benjamini 
and Hochberg [28] is more practical for proteomic or genomic experiments comparing several 
potential biomarkers among patients [29, 30]. In this method, unadjusted p-values are first 
ordered from smallest to largest, and the rank is recorded. The adjustment to the error rate is 
calculated as α*m/k for each p-value, where α is the error rate, m is the rank, and k is the total 
number of comparisons made. The adjusted p-value is referred to as the Q-value in the 
Benjamini-Hochberg approach. This correction is more suitable for experiments with large k as it 
is less likely to overlook statistically significant results that may be masked by more conservative 
approaches.   
2.2.2 Sensitivity and Specificity 
Sensitivity and specificity are common statistical measures used to assess the diagnostic 
accuracy of a biomarker [25]. Sensitivity refers to the probability of identifying a disease when it 
is actually present in the individual, whereas specificity refers to the probability of correctly 
dismissing individuals without the disease. Results for sensitivity and specificity can be 
classified as true positives (sensitivity), false positives (1-specificity), true negatives 
(specificity), and false negatives (1-sensitivity). Figure 4 illustrates these measures.  
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Figure 4. Sensitivity and specificity calculations for a diagnostic test 
 
 In most cases, it is desired to find a certain threshold that will maximize both sensitivity 
and sensitivity. For diagnostic tests, this will provide the most accurate results for discrimination 
between patients with and without disease. Sometimes, it is more convenient to control for 
higher levels of sensitivity if the benefit of identifying true positives highly outweighs the cost of 
false positives. This is such the case in biomarker analysis for CAD. The cost of misdiagnosing 
patients with clinically relevant CAD is too great, while misdiagnosing a symptomatic patient 
without CAD will only expose them to a cardiac catheterization procedure. Valid diagnostic tests 
should maintain very high levels of sensitivity. In order to characterize measures of sensitivity 
and specificity, receiver operating characteristic curves are usually generated.  
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2.2.3 Receiver Operating Characteristic Curves 
The Receiver Operating Characteristic (ROC) curve is a way to visualize and gauge the 
performance of a set of classifiers [31]. ROC analysis is the principal method for evaluating 
sensitivity and specificity of a classifier and proves to be a useful tool in the evaluation of 
biomarkers [26]. In general, a measurement of the area under the ROC curve (AUC) is reported 
to compare the intrinsic accuracy of different tests [32]. The ROC curve is generated by plotting 
a set of thresholds according to their corresponding true-positive and false positive rates, or 
sensitivity and 1-specificity.  
 When generating ROC curves for logistic models with several predictors, retrospective 
calculations of the ROC curve tend to give inflated assessments of score performance [33]. A 
predictive model will almost always fit better to the data it was constructed around than when 
applied to future data. This is because the ROC curve is generated by a process of resubstitution, 
where the model is constructed using the available data, and then validated on the same data 
[34]. Some more advanced techniques for handling the upward bias of the ROC curve have been 
discussed [35], but among the simplest and most common methods are k-fold cross validation 
and external validation. 
K-fold cross-validation is an internal validation method for estimating the prediction 
error. In this process, the data is split into k number of blocks. A predictive model is generated 
based on the K-1 partitions and used to score the Kth block (figure 5). This process is repeated 
until predicted probabilities have been generated for all the observations. 5-fold and 10-fold 
cross-validation are the most common forms of K-fold cross validation, using 80% of the data to 
score the other 20%, or 90% of the data to score the other 10%, respectively [36].   
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External validation is one of the best ways to determine how well a logistic model can 
perform in clinical applications [37]. The data made available to the researchers or the 
statistician is used as a training set, where the predictive model is generated. The test set comes 
from additional experiments where the data has not been seen prior to developing the model. 
This can sometimes be emulated in an internal validation process where the data set is split into a 
training set and validation set prior to analysis. The validation data is then scored using the 
predictive model from the training set. In order to use this technique to estimate the prediction 
error of a model, the data set needs to be sizable enough to split into two separate data sets (ex. 
2/3 data for the training set, 1/3 data for the validation set) [36].  
 
Figure 5. Example of 5-fold cross-validation  
Four blocks are used as the training set and the model is validated on the fifth block of data. This 
process is repeated until cross-validated probabilities are calculated for all the blocks of data. 
 
The ROC curve has been widely used to illustrate the sensitivity-specificity trade of in 
medical diagnostic testing, but newer methods are currently being applied to analyses to increase 
the clinical usefulness of statistics reporting on the added predictive ability of new biomarkers. 
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3.0  CLINICAL APPLICATION 
The data set examined in this thesis originates from a study by LaFramboise et al., focusing on 
the identification of circulating proteins for the diagnosis of coronary artery disease [14]. This 
single-center study interrogated 359 serum samples for proteins from symptomatic patients 
referred for cardiac catheterizations from an emergency room or heart clinic. The proteins chosen 
for research have been previously identified as potential biomarkers for cardiac conditions or 
pathways involved with these conditions. The hypothesis of the study suggests that a 
combination of proteins known to be involved with multiple pathways of atherosclerosis can be 
used to develop a non-invasive alternative to coronary angiography for detection of CAD. This 
study is unique, in that it applies to the specific population of symptomatic patients that are 
referred for cardiac catheterization. 
The proteomics analysis was conducted in two stages. In stage one, 239 samples (138 
with CAD and 101 with normal coronary arteries) were assayed for 24 proteins. A scoring 
algorithm was generated off these 239 samples to measure the predictive ability of the proteins. 
This scoring algorithm was developed with a Monte Carlo optimization technique using a 
Metropolis algorithm [38] to derive the numerical coefficients, rather than the maximum 
likelihood approach used in logistic regression. 5-fold cross validation was used to estimate the 
bias in the ROC curve and to generate relevant sensitivity and specificity measurements. In the 
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following analysis, this process is duplicated using logistic regression rather than methods used 
to generate the previous scoring algorithm. 
In stage 2, assays were run on 120 additional samples (71 with CAD and 49 with normal 
coronary arteries) for validation of the algorithm, but for economic reasons, the researchers 
excluded assaying for proteins the scoring algorithm found to be poor predictors for disease. 
Therefore, patient samples in this stage were only assayed for 11 of the proteins in the study. The 
addition of the 120 samples in stage 2 of the study was intended to externally validate the 
predictive ability of the scoring algorithm, comparable to the external validation process 
mentioned in section 2. Through statistical processes, it was determined the 11 proteins in the 
stage 2 data set were sufficient for this analysis. 
Clinical characteristics for these subjects were obtained retrospectively, so there are some 
missing data encountered where clinical information could not be determined for the patient. No 
clinical characteristics were made available for the validation data set. Figure 6 shows a 
summary of the data that was available for this project [14]. 
 
Figure 6. Data set components in stage 1 and stage 2 of the original study 
Stage 1 
239 observations 
Data available for all 24 
proteins 
Clinical characteristics 
available for 224 patients 
Predictive model is contructed 
using this data 
Stage 2 
120 observations 
Data only available for 11 
proteins 
No clinical characteristics 
available 
Predictive model is validated 
using this external data set 
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The goal of the following analysis was to suggest a multi-marker panel, derived from the 
statistical methods covered in section 2, to be considered, in addition to previous results, for 
future studies. The analysis expands upon the original study by incorporating clinical 
characteristics and measuring the added effect of a multi-marker panel to these characteristics in 
the prediction of CAD.  
A secondary analysis was included, following discovery of biomarkers with high 
predictive power, to measure whether or not a serum protein profile could be used on its own as 
a diagnostic tool, or if adding clinical characteristics to the algorithm could enhance predictive 
measures.  
To sum up, the analysis will answer three questions: 
1. Can a combination of circulating proteins in a symptomatic patient’s serum 
predict coronary artery disease? 
2. Can the predictive power of currently used clinical risk factors for heart disease 
be enhanced by protein biomarkers? 
3. If a predictive model is generated based only on proteomic factors, can this model 
be enhanced by clinical risk factors for heart disease? 
3.1 STATISTICAL METHODS 
A preliminary analysis was conducted to emulate the objective of the original study by 
LaFramboise et al – to derive a statistically significant multi-marker panel for that can accurately 
discriminate between patients with and without coronary artery disease. The rest of the analysis 
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addresses the added predictive ability of multiple biomarkers to clinical characteristics that are 
commonly used to assess risk of coronary disease. Logistic regression and ROC curves are the 
primary statistical methods used for the analysis. 
3.1.1 Preliminary analysis: evaluation of proteomic biomarkers 
Before analysis was conducted, one-third of the data (120 samples in stage 2) were set aside to 
use as a validation set. The remaining 239 samples were used as a training data set.  
Descriptive analysis of proteins 
Descriptive analysis was performed on the proteins of the 239 samples (stage 1) in the training 
data set, and values of the proteins were compared across the disease groups to identify which 
proteins projected higher concentrations in patients with CAD. Imputation of 3 missing values 
was performed for MPO, Fibrinogen, and Leptin by replacing the missing value with the average 
level of the protein, conditional on the disease group. The Wilcoxon rank sum test was used 
under the null hypothesis that there were no statistically significant differences in protein 
concentrations among the groups. P-values were adjusted by the Benjamini-Hochberg (B-H) 
method [28] to control for multiple comparisons. The false discovery rate (FDR) was set at .05 
and resulting Q-values less than this value were determined to be statistically significant. Results 
from the statistical tests identified proteins that would serve as useful biomarkers due to more or 
less of a presence in patients with disease.  
Histograms of proteomic factors were generated to identify the distributions of the 
protein concentrations among the patients in the study. Heavily skewed concentrations were 
normalized by a natural logarithmic transformation to the data.  
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Descriptive statistics were also generated for the external data set of 120 patients (stage 
2) for comparison to the cohort tested in the training data. Differences between the validation set 
and the training set may be a cause of variability in the technical procedures during the assay 
process. 
Multivariate logistic regression of protein biomarkers 
Protein concentrations, recorded on the original-scale or log-scale, were first factored by 
quartiles to categorize variables into low, medium, high, and very high intensities. The 
categorization of the variables was used to identify the pattern of association during univariate 
analyses. Univariate logistic regressions performed on the quartiled predictors produced odds 
ratios for quartiles 2-4, using the first quartile as the reference category, and a trend test was used 
to formally test whether or not there is an uniform increase (or decrease) in odds ratios across the 
quartiles. A multivariate logistic regression model was constructed based on a stepwise variable 
selection process with these factored covariates to assess the probability that patients with higher 
levels of a given set of proteins have CAD. This was followed up by analysis on the continuous 
form of the variables to produce more clinically relevant results. 
For variables that appeared to follow a trend with the log-odds of disease, the functional 
form of the continuous covariate was investigated using first and second degree fractional 
polynomials. Fractional polynomial transformations that produced statistically significant 
improvements to the fit of the model were used for each covariate. Once the functional form of 
the variable was determined, a subsequent univariate analysis was carried out on the continuous 
form of the covariates. OPN unquestionably held the most statistically significant relationship 
with CAD from the univariate tests. Since the purpose of the analysis was to identify an effective 
multi-marker panel for discrimination among patients with and without CAD, logistic 
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regressions were run on the main effects once again, adjusting for OPN. Associations were tested 
at the .05 significance level. 
 After appropriate functional forms were found, a forward stepwise variable selection 
process was conducted on remaining variables using a probability of entry into the model of 0.05 
and probability of removal from the model to be 0.1. All variables were entered into the model 
building process using their functional form as determined by the univariate analyses.  
ROC analysis of the protein biomarker model 
A naïve estimator of the area under the ROC curve (AUC) using the resubstitution method was 
recorded for comparison to the cross-validation methods. K-fold cross-validation was performed 
on the data set to estimate the error from the overly optimistic curve generated by resubstitution. 
5-fold cross-validation was performed first to mimic the methods of the original study and 
compare the predictive model presented in this thesis with panels of markers identified by the 
original scoring algorithm. This was followed up by 10-fold cross-validation to detect any bias-
variance tradeoff in the selection of k for this sample. 
 A validation procedure, using an additional 120 samples from a similar cohort, was 
conducted to measure the predictive model’s ability to discriminate among “unseen” data. These 
samples were scored according to the final model derived from the first 239 samples, and 
statistics from an ROC analysis were compared to the cross-validated estimates.  
3.1.2 Addition of proteomic biomarkers to clinical characteristics 
The main focus of this work was to reveal how the proteomic biomarkers discovered in the 
preliminary analysis contributed to the predictive power of common clinical risk factors for heart 
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disease. This extended the hypothesis of the original study to include clinical variables in the 
discriminatory process. Age, smoking status (never, former, current), diabetes status (yes/no), 
and BMI calculations were studied to identify whether or not the factors had associations with 
coronary artery disease. BMI calculations were split into categories according to the Center for 
Disease Control (CDC), listed in table 1. This analysis was restricted to 224 observations, 
omitting patients whose clinical characteristics were unavailable.  
Table 1. BMI Categories outlined by the Center for Disease Control 
BMI (kg/m
2
) Weight Status 
Below 18.5 Underweight 
18.5 – 24.9 Normal 
25.0 – 29.9 Overweight 
30.0 and above Obese 
 
Descriptive analysis and logistic regression for protein biomarkers and clinical 
characteristics 
Descriptive analyses were carried out on each of the clinical variables to determine any 
differences between the CAD and Normal groups. A Student’s t-test was used to test the 
continuous variable age, and Chi-Square tests were used to test the other categorical variables in 
order to determine statistically significant associations with the disease group.  
 Univariate logistic regressions were carried out for each clinical variable to identify 
statistically significant linear relationships with CAD. Factors showing strong associations with 
disease were entered into a multivariate predictive model for CAD. The predictive model was 
then enhanced by adding proteomic biomarkers to the modeling process, both as quartiles and in 
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the continuous form in separate analyses. A final model that represented both a multi-marker 
panel from the preliminary proteomics analysis and important clinical risk factors was evaluated 
for predictive accuracy. 
ROC analysis of the multivariate model 
An ROC curve was generated for the predictive model consisting of clinical characteristics to use 
as a baseline measurement for comparison when new biomarkers are added to the model. For this 
part of the analysis, an external validation set was not available; the data set only provided 
clinical characteristics for 224 samples. Therefore, evaluation methods for the predictive models 
were restricted to k-fold cross validation – specifically, 10-fold cross validation, using 90% of 
the data as the training set and 10% as the validation set. 
Biomarkers from the multi-marker panel identified in the proteomics analysis were added 
sequentially to the model consisting of clinical characteristics to measure the added predictive 
ability of the biomarkers. Improvement was determined by differences in the specificity at high 
sensitivities.  
Unless otherwise stated, all statistical tests were conducted at a 0.05 significance level. 
The B-H method for multiple comparisons was restricted to comparative tests across the disease 
groups, as the conservative nature of the method did not affect the variable selection process in 
logistic regression. 
Software 
The analysis was performed mainly using SAS 9.3 statistical software. Fractional polynomials 
were analyzed using the fracpoly command in Stata 12. Graphics were generated by Stata 12. 
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3.2 RESULTS 
3.2.1 Preliminary Results: Evaluation of proteomic biomarkers 
3.2.1.1 Descriptive Analysis of Proteins 
Tables 2-4 include descriptive statistics – the 24 proteins across 239 patient samples. Proteins 
were grouped by the scale they were measured on (μg/mL, ng/mL, pg/mL). The “CAD” column 
represents patients with clinically relevant coronary artery disease, and the “Normal” column 
represents patients with normal coronary arteries, or clinically irrelevant coronary disease. The 
Q-values are the Benjamini-Hochberg equivalent of the p-value. Fourteen proteins were found to 
have statistically significant differences in patients with significant CAD versus those with 
normal coronary arteries, controlling for a false discovery rate (FDR) of 0.05. All significant 
findings were found to be elevated in the CAD group, except for Apo-A1, which appeared to be 
of lesser quantities in the CAD group. These 14 proteins were carried over for further analysis. 
Distributions of the 14 proteins up-regulated/down-regulated during times of coronary 
artery disease were examined. Apo-B100 and MPO appeared to follow a normal distribution in 
the CAD and Normal groups. All other proteins had heavily skewed-right distributions in both 
disease groups. A natural logarithmic transformation was applied to this data to fix the skew. 
Descriptive statistics for the stage 2 data can be found in Appendix A.
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Table 2. Stage 1 Protein Descriptive Statistics (nanograms/mL)  
 
 Combined  CAD  Normal   















OPN (ng) 239  138 49.6 41.6 13.8 28.6 55.7  101 15.8 15.9 6.7 10.9 21.6 <.0001 <.0001 
VCAM (ng) 239  138 1175.1 500.9 940.0 1152.1 1538.8  101 856.7 365.2 683.8 903.6 1193.5 <.0001 <.0001 
IL6 (ng) 239  138 0.9 1.2 0.04 0.3 1.3  101 0.6 1.1 0.02 0.04 0.6 <.0001 .0001 
MPO (ng) 239  138 619.8 370.1 380.7 586.4 915.2  101 451.2 267.3 297.2 441.0 700.3 .0003 .0006 
MMP7 (ng) 239  138 5.4 2.4 3.7 4.8 6.1  101 4.8 3 3.0 4.2 5.3 .0006 .0013 
Resistin (ng) 239  138 104.6 70.6 52.8 90.1 139.7  101 81.9 62.8 47.0 71.8 110.8 .0020 .0038 
MMP1 (ng) 239  138 5.3 2.4 3.7 5.0 6.6  101 4.8 2.2 3.1 4.4 6.0 .0452 .0723 
Leptin (ng) 239  138 10.6 15.5 3.1 5.0 13.8  101 13.9 17.6 3.1 5.9 16.8 .2625 .3210 
TIMP1 (ng) 239  138 329.3 87.9 269.3 323.4 370.9  101 320.1 112.2 238.9 310.5 372.1 .2675 .3210 
TM (ng) 239  138 1.4 0.4 1.1 1.3 1.5  101 1.4 0.9 1.0 1.3 1.6 .3341 .3739 
Pecam-1 
(ng) 
239  138 35 25.3 26.6 26.6 41.8  101 32.1 29 18.1 26.6 40.4 .3437 .3739 
MCP1 (ng) 239  138 3.3 3.4 1.2 2.4 4.5  101 3.1 3.5 1.3 2.1 3.6 .3583 .3739 
E-Selectin 
(ng) 
239  138 34.3 16.5 21.2 34.2 44.3  101 33.9 19.1 22.5 31.7 44.7 .5686 .5686 
 






Table 3. Stage 1 Protein Descriptive Statistics (micrograms/mL) 
 
 Combined  CAD  Normal   















Fibrinogen (μg) 239  138 19 59.2 3.4 6.0 12.6  101 4.1 6.3 1.8 3.2 5.6 <.0001 <.0001 
Apo-A1 (μg) 239  138 154.2 134.8 57.8 117.0 195.6  101 300.6 258.8 114.0 223.2 385.7 <.0001 <.0001 
Apo-B100 (μg) 239  138 339.1 80.6 233.5 299.9 370.9  101 295.6 80.6 206.8 265.5 328.9 .0001 .0003 
CRP (μg) 239  138 0.8 1.5 0.1 0.5 1.4  101 0.3 0.6 0.1 0.3 0.8 .0038 .0065 
L-Selectin (μg) 239  138 1.1 0.3 0.9 1.1 1.3  101 1.1 0.3 1.0 1.1 1.3 .1482 .2760 
Acrp30 (μg) 239  138 4.8 3.5 2.7 4.1 6.2  101 5.3 3.8 3.0 4.8 7.7 .2650 .3210 
 










Table 4. Stage 1 Protein Descriptive Statistics (picograms/mL) 
 
 Combined  CAD  Normal   















IL10 (pg) 239  138 7.5 18.2 2.6 3.65 5.9  101 3.2 3.6 1.2 2.1 3.5 <.0001 <.0001 
IL1β (pg) 239  138 113.7 168.2 4 23.2 152.3  101 48.9 120.1 1.9 7.0 38.0 <.0001 <.0001 
NT-pBNP (pg) 239  138 101.7 202.5 12.3 31.8 93.9  101 41.1 111.6 7.8 15.8 32.6 <.0001 .0001 
IFNγ (pg) 239  138 4.2 7.7 0.5 2.1 4.6  101 4 12.9 0.2 1.4 2.9 .0010 .0020 
TNFα (pg) 239  138 15 19.4 3.1 8.7 17.8  101 22.4 73.7 0.0 5.4 16.9 .0998 .1497 
 
Number of observations, average, standard deviation and interquartile range for CAD and Normal groups. The Q-value is the B-H analog of the P-
value. 
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3.2.1.2 Logistic Regression Modeling of Proteins 
Univariate regressions for the 14 up-regulated/down-regulated proteins (identified by the 
previous comparative tests) uncovered statistically significant relationships with disease status. 
For proteins entered as categorical variables into a univariate logistic regression model, higher 
quartiles produced higher odds ratios with disease compared to concentrations in the first 
quartile. Trend tests on the quartiles of the continuous covariates identified increasing odds ratios 
among all variables (table 5). Graphs of the odds ratios for the quartiles of variables can be found 
in Appendix A. 
Univariate regressions on the continuous form of the 14 proteins also produced 
statistically significant relationships with CAD. While categorization had resulted in increasing 
odds ratios for most all of the proteins, nonlinearity in the proteins’ continuous form was still 
assessed. Fitting each univariate regression (using the continuous form of the variables) with 
fractional polynomials identified a nonlinear function for IL1β that produced a better fit for the 
model. A cubic transformation was applied to capture the functional form of this variable. 
Analysis of second degree fractional polynomial transformations produced statistically non-
significant results for all main effects. 
Table 6 shows the results of both the unadjusted logistic regressions and regressions 
adjusted for OPN. Apo-A1 and NT-pBNP produced statistically non-significant relationships 
with disease when adjusted for OPN. Odds ratios in this table are calculated according to unit 




Table 5. Odds ratios and trend tests for univariate regressions of factored protein concentrations  
 
 
















































































































































































Table 6. Univariate regressions for the continuous form of the protein concentrations 
  Unadjusted  Adjusted for OPN 
Variable STD Odds-ratio P-Value  Odds-ratio P-Value 
OPN* 1.05 4.06 <.0001  - - 
VCAM* 0.44 2.34 <.0001  1.39 .0835 
Apo-A1* 1.00 0.43 <.0001  0.77 .1530 
IL-10* 3.16 3.24 <.0001  2.18 .0104 
Fibrinogen* 1.12 2.53 <.0001  1.96 .0012 
IL1β* 2.92 1.92 <.0001  2.73 <.0001 
NT-pBNP* 1.83 1.92 .0002  1.11 .5979 
Apo-B100 83.26 2.29 .0003  1.79 .0014 
MPO 340.32 1.97 .0009  2.77 <.0001 
IL-6* 2.17 1.76 .0011  2.04 <.0001 
CRP* 1.51 1.57 .0019  1.43 .0315 
MMP7* 0.46 1.54 .0034  1.34 .0825 
Resistin* 0.74 1.57 .0034  2.93 <.0001 
IFNγ* 5.54 1.70 .0054  1.78 .0004 
  *log-transformed variable 
A forward stepwise selection process of the predictors to determine a final model resulted 
in a panel of 4 distinct markers – OPN, IL1β, Apo_B100, and Fibrinogen. The resulting model 
was fit using both categorical (quartiles) and continuous forms of the variables. 
The multivariate model containing the quartiles of the covariates (table 7) indicate that 
the odds of disease are elevated for higher quartiles compared to the lowest quartile. The 















Intercept -4.76 0.92 <.0001 -- -- 
OPN      
2 1.15 0.49 0.0187 3.15 1.21 to 8.18 
3 2.19 0.51 <.0001 8.95 3.32 to 24.09 
4 4.35 0.76 <.0001 77.54 17.66 to 340.60 
IL1β      
2 0.95 0.51 0.0634 2.58 0.95 to 7.01 
3 1.75 0.53 0.001 5.75 2.03 to 16.27 
4 2.71 0.57 <.0001 15.01 4.94 to 45.61 
Fibrinogen      
2 0.84 0.49 0.0868 2.31 0.89 to 6.04 
3 1.26 0.52 0.0152 3.54 1.28 to 9.82 
4 1.45 0.55 0.0081 4.26 1.46 to 12.46 
Apo-B100      
2 0.41 0.76 0.5922 1.51 0.34 to 6.73 
3 1.74 0.77 0.0239 5.68 1.26 to 25.66 
4 1.85 0.75 0.0135 6.34 1.46 to 27.44 
 
For the model featuring continuous covariates (table 8), Apo_B100 was recorded on the 
original scale while the other 3 markers were measured on the natural logarithmic scale. IL1β 
entered the model in its functional form as determined by the fractional polynomial 
transformation. All first-order interactions among the covariates were determined to be not 
statistically significant during the modeling process.   
 









95% CI Min Max 
Intercept -7.31 1.16 <.0001 -- -- -- -- 
OPN* 1.43 0.22 <.0001 4.18 2.70 to 6.47 0.13 5.32 
IL1β** 0.52 0.11 <.0001 1.68 1.35 to 2.09 -4.38 4.07 
Apo_B100 0.008 0.002 0.0015 1.01 1.00 to 1.01 0.36 529.21 
Fibrinogen* 0.53 0.19 0.0065 1.70 1.16 to 2.48 -0.63 6.10 
*natural logarithmic scale  **functional form: ln(IL1β)3 
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All coefficients for main effects in this final model were statistically significant (all p ≤ 
0.006), suggesting that removal of one of the variables would significantly reduce the fit of the 
model. Interpretations of coefficients can be made in respect to the log odds of CAD, taking into 
account the functional form of the main effects within the model, while adjusting for other 
covariates. For example, the log odds of CAD would increase at a rate of 1.43 for every unit 
increase in the natural log of OPN. It may make more sense to report these numbers as odds 
ratios though. The odds of a patient having CAD are approximately 4 times greater for every unit 
increase in the natural log of OPN. Odds of disease increase at a rate of 68% for every unit 
increase in the cubic function of the natural log of IL1β, 0.8% for every unit increase in Apo-
B100, and 70% for every unit increase in the natural log of Fibrinogen.  
An ROC analysis was conducted for this final model including continuous covariates in 
the next steps. 
3.2.1.3 ROC Analysis of Protein Model 
The optimistic estimator for the AUC was .8816. 5-fold and 10-fold cross-validation was 
performed 10 times each, and results were averaged to obtain a correction for the predicted 
probabilities and the ROC curve. The AUC estimates from 5-fold and 10-fold cross-validation 
were 0.8611 and 0.8632, respectively, which are lower than the original estimate, but only by a 
small amount. 5-fold cross-validation did not appear to introduce much bias to the prediction 
error, as the results obtained by both 5-fold and 10-fold cross-validation were similar. Table 9 
shows the AUC estimate for each method, the exact sensitivity (SN) of ~95%, and specificities, 
the ability to identify true negatives, at 90%, 95%, and 98% sensitivities (SP90, SP95, and S98). 
Where an exact sensitivity of 90, 95, or 98 was attainable, the closest level of sensitivity to each 
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value was used. Controlling for 95% sensitivity, 38% specificity was attained using the 
predictive model to classify patients within the sample of 239. 
Validation on the external data set, the 120 patients of “stage 2,” saw lower 
discrimination among the patients, but with an AUC statistic at .7077, an impressive level for a 
predictive model. Performance for validation usually declines because the predictive model was 
built without “seeing” this data. Maintaining 95% sensitivity, the predictive model generated on 
the 239 patients had a specificity of 10% when applied to external data. This may have 
implications for instability in the predictive model in clinical practice, or that patients in the 
additional cohort displayed significantly different characteristics than the first cohort. Further 
mention of this variability can be found in the discussion. 
 
Table 9. AUC, Sensitivity, and Specificity from Cross-Validated Results for the protein-only model  
 
Method AUC SN SP90 [95% CI] SP95 [95% CI] SP98 [95% CI] 
Resubstitution .8816 94.9 .505 [.404, .605] .436 [.338, .538] .307 [.221, .408] 
5-Fold Cross Validation .8611 94.9 .515 [.414, .615] .376 [.283, .479] .356 [.265, .459] 
10-Fold Cross 
Validation 
.8632 94.9 .515 [.414, .615] .386 [.292, .489] .347 [.256, .448] 
External Validation .7077 95.7 .225 [.122, .370] .102 [.038, .230] .061 [.016, .179] 
 
Column SN is the closest rounded estimate for 95% sensitivity. The last 3 columns represent corresponding 
specificities at 90, 95, and 98 percent fixed sensitivities with 95 percent confidence intervals. 
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Figure 7. Validation methods for the ROC curve  
In 5-fold and 10-fold cross-validation (top) the lighter line represents the cross-validated probabilities and the darker line is the curve 
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3.2.2 Added effect of biomarkers to clinical characteristics 
The results in this section demonstrate the added predictive ability of a multi-marker panel for 
CAD among symptomatic patients. As clinical characteristics were scarce, only gender, diabetes, 
BMI, hypertension, smoking, and age factors were analyzed. 
3.2.2.1 Descriptive Analysis of Clinical Characteristics 
For the full data set, 138 symptomatic patients were diagnosed with CAD and 101 patients were 
considered to have insignificant disease according to catheterization results. Fifteen of these 
patients were removed from the analysis due to the absence of clinical information for those 
subjects, leaving 123 samples in the CAD group and 101 samples in the Normal group. Of the 
clinical variables examined, only age, diabetes status, and smoking status were significantly 
different among the CAD and Normal groups. Patients in the CAD group were, on average, older 
than the Normal group (p = .0096), and positive associations with CAD were confirmed for 
patients with diabetes (p = .0087) and smokers (p = .0071), according to the Student’s t-test for 
continuous variables and the chi-square test for categorical variables. BMI categories, 
hypertension status, and gender were determined to have statistically non-significant associations 
with CAD (all p ≥ .40). 
Univariate regressions on the clinical variables produced significant linear relationships 
with the log-odds of significant CAD for age, diabetes status, and a current smoking status. All 
other clinical variables that showed insignificant associations with disease status from the 






Table 10. Descriptive statistics of clinical characteristics 
 Combined  CAD  NORMAL  
Clinical Characteristics N  N AVE STD  N AVE STD P-Value 
AGE (years) 224  123 62.3 12.1  101 58.1 11.6 .0096 
      
 Combined  CAD NORMAL  

































































Table 11. Univariate regressions on clinical characteristics 








Diabetes 2.306 .0097 
Age 1.030 .0107 
HTN 1.241 .4311 
Gender .9578 .8723 
BMI 
  -overweight 





3.2.2.2 Multivariate model building involving proteins and clinical characteristics 
A full multivariable regression process was carried out on proteins and clinical characteristics in 
the data set (categorical form of covariates can be found in Appendix A). The final multivariate 
model (table 12) produced the same 4-marker panel derived from the preliminary analysis, along 
with indicator variables for diabetes and current smokers. According to the model, these clinical 
factors accounted for a 3-fold increase in odds of disease for smoking patients or diabetics. Age 
dropped out of the final model due to lack of a statistically significant relationship with disease 
status once adjusted for additional predictors. The estimates for the four protein biomarkers in 
the final model remained statistically significant even with the addition of further clinical risk 
factors (age, BMI, and HTN), proving the validity of these predictors. 
The final model including both clinical characteristics and proteomic biomarkers had a 
high level of discrimination among patients (AUC = .8805), and there was improved ability to 
detect true negative results while controlling for high levels of sensitivity (see table 13). 
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Standard Error P Value Odds Ratio 95% CI Min Max 
Intercept -8.412 1.339 <.0001 -- -- -- -- 
Smoking Status 1.210 .5270 .0217 3.353 1.194 to 9.420 -- -- 
Diabetes 1.083 .4373 .0133 2.952 1.253 to 6.569 -- -- 
OPN* 1.462 .2367 <.0001 4.313 2.712 to 6.860 .130 5.32 
IL1β** .5015 .1229 <.0001 1.651 1.298 to 2.101 -4.38 4.07 
Apo_B100 .0091 .0028 .0010 1.009 1.004 to 1.015 .363 529.21 
Fibrinogen* .5942 .2168 .0061 1.812 1.812 to 2.771 -.628 6.10 
Method AUC SP90 [95% CI] SP95 [95% CI] SP98 [95% CI] 
Resubstitution .9006 .6536 [.552, .744] .4753 [.376, .577] .3861 [.292, .489] 
10-Fold  
Cross Validation 
.8805 .5941 [.482, .680] .3861 [.292, .489] .3366 [.248, .438] 
*natural logarithmic scale  **functional form: ln(IL1β)3
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Table 13. AUC, Sensitivity, and Specificity from Cross-Validated Results for the protein-only model 
Model AUC SP90 SP95 SP98 
Current Smoker, 
Diabetes 
.5787 .0396 0 0 
Additional marker 
(Adjusted for Current 
Smoker and Diabetes) 
AUC 
(difference) 
SP90 [95% CI] 
(difference) 




.4951 [.395, .596] 
(+.4555) 




.2574 [.169, .345] 
(+.2178) 




.3861 [.292, .489] 
(+.3465) 




.2970 [.212, .397] 
(+.2574) 
.2277 [.152, .324] .0396 [.012, .104] 




.5941 [.482, .680] 
(+.2574) 
.3861 [.292, .489] .3366 [.248, .438] 
44 
4.0 DISCUSSION 
Preliminary analysis: proteomic biomarkers 
The final multi-marker panel, consisting of OPN, IL1β, Apo-B100, and Fibrinogen, differed 
from any of the multi-marker panels in the original study. Each individual marker appeared in at 
least one of the proposed panels in the original study, however there were no 4-marker panels 
identical to the one derived from the logistic regression process. Differences in results between 
this analysis and the original study may be attributed to the methods used in generating a 
predictive model or scoring function. The maximum likelihood approach used in this analysis for 
estimating the model’s coefficients provided a statistical advantage to developing a multi-marker 
panel with the best diagnostic ability. The 4-marker panel performed less well when applied to 
external data from an additional cohort, but this was done without first calibrating the model. 
Smoothing parameters were not used in this analysis, but may be used in a future analysis or 
study to improve prediction on external data. There may have also some variability in the protein 
measurements during the proteomics phase of the experiment due to the validation samples being 
run on a separate lot of plates and reagents than the samples used for the training data. 
Compared with the multi-marker panels suggested by LaFramboise et al, the 4-marker 
panel derived from the logistic regression process was similar. The best 4-marker panels derived 
by the study’s scoring algorithm had AUC measurements ranging from .82-.84 and specificities 
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of 43% - 58% at 95% sensitivity, while the predictive model generated here produced an AUC of 
.86 and 38% specificity achieved at 95% sensitivity.  
 Concentrations of OPN produced the strongest relationship of any protein, which is a 
significant result of this analysis in itself, as OPN has been linked to heart disease through recent 
studies [39]. In regards to its relationship with coronary disease, OPN is a glycoprotein/cytokine 
of the extracellular matrix that has shown implications of roles in cardiac remodeling and fibrosis 
[40]. Other studies suggest that OPN is associated with calcification in coronary arteries [41, 42]. 
However, up-regulation of this protein has been linked to many other pathologies as well, 
including myeloma, multiple sclerosis, bone destruction, and cancer, preventing a direct 
association with heart disease to be made [43]. This makes it difficult to draw conclusions on the 
clinical usefulness of OPN as a biomarker for CAD without further understanding of the 
protein’s precise function. 
IL1β is a cytokine of the interleukin family known to be involved in inflammatory 
response. The inflammatory process has been discussed as a significant mediator in the 
development of atherosclerosis, and the gene encoding the IL1β protein has been linked to 
coronary artery disease in Brazilian populations [44]. Apo-B100 is a lipid binding protein that is 
responsible for carrying low density lipoproteins (LDL, aka “bad cholesterol”) to tissues. Apo-
B100 has been declared as a more reliable indicator of risk of heart disease than LDL and a 
standardized assay for the protein can be used clinically [45]. Fibrinogen is known to play a role 
in blood clot formation and concentration levels have been notably increased in patients with 
cardiovascular disease. Thrombosis, the formation of blood clots, has been recognized as the 
basis for many cardiac cases involving myocardial infarction, ischemic death, and unstable 




Proteomic biomarkers add predictive value to clinical characteristics 
The addition of a proteomic multi-marker panel to common clinical risk factors of heart disease 
greatly improved discrimination among symptomatic patients. For the sample of symptomatic 
patients studied, the data resembled the current status quo, where the use of clinical 
characteristics provides zero ability to detect a patient who does not need to undergo 
catheterization. None of the clinical characteristics had adequate discriminatory power before the 
inclusion of proteins. The added discriminatory power of OPN, alone, accounted for most of the 
increase in predictive power, but the ability to classify patients with normal coronary arteries 
while maintaining a high sensitivity was the best when Fibrinogen, IL1β, and Apo-B100 were all 
present. The analysis demonstrated that the use of protein biomarkers for coronary artery disease 
can identify approximately thirty percent of patients for whom cardiac catheterization would be 
unnecessary. 
Lastly, the analysis involving clinical characteristics was very limited. It would have been 
beneficial to incorporate patient cholesterol profiles and family history among other risk factors 
into the analysis. Ideally, it would be of interest to measure the impact biomarkers have on 
currently used scoring systems for pretest probability or likelihood of CAD. Additional studies 
should measure all risk factors of a patient that are currently used in practice to diagnose the risk 
of heart disease and the effect new biomarkers will have in determining a patient’s pretest 
probability or likelihood of disease. This alludes to a chief argument against biomarker studies – 
that efforts should rather be focused on improving current diagnostic methods. While one 
obvious approach to this argument would be to improve medical imaging techniques for 
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coronary angiography, one could also argue to improve current diagnostic methods by adding 
new biomarkers to the current set of clinical risk factors used by professionals.    
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5.0  CONCLUSION 
Throughout this thesis, evaluation of diagnostic biomarkers has been discussed in regards to 
coronary artery disease, where the current diagnostic method is starting to become costly. 
Common statistical methodologies regarding biomarker experiments, including logistic 
regression and ROC curves, were demonstrated on a clinical study intending to identify multiple 
proteins that can accurately diagnose cardiac patients that are normally referred for coronary 
angiography. The statistical analysis confirmed the predictive ability of protein biomarkers that 
was discovered in the previous study, but also added further insight into the public health matter 
by incorporating clinical characteristics. The primary focus of the analysis resulted in the 
following conclusion: A multi-marker panel featuring OPN, IL1β, Apo-B100, and Fibrinogen, 
based on the serum protein profiles of symptomatic patients, can be used in conjunction with 
clinical risk factors of heart disease (specifically diabetes and smoking status) to improve 
discrimination between those with clinically significant coronary artery disease and those with 
“normal” coronary arteries that do not require cardiac catheterization.  
Screening symptomatic patients prior to cardiac catheterization with a blood assay can be 
advantageous if the goal is to reduce the number of patients exposed to unnecessary operations. 
In order to prevent a high number of patients that actually do have coronary artery disease from 
being misclassified, only a small number of patients that do not require angiographic testing 
could be identified. This may seem like a poor outcome, but the current status quo identifies zero 
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percent of these patients. Therefore, even identifying one of these symptomatic patients with 
clinically insignificant coronary artery disease can be labeled a success.  
The main issue to consider before implementing a blood test as a new diagnostic 
procedure would be whether or not it is worth the risk of dismissing a single patient that has 
clinically significant coronary artery disease. While a multi-marker panel has proven ability to 
classify patients into disease and non-disease groups, there is still a chance of error with this type 
of test, and it is still uncertain whether or not the benefits outweigh the costs when used in 
clinical practice. However it is also undeniable that the future landscape of healthcare in the 
United States, particularly with the inclusion of the Affordable Care Act, will find these types of 
screening procedures more and more attractive, especially for procedures such as cardiac 
























1. DESCRIPTIVE STATISTICS OF THE STAGE 2 (VALIDATION) DATA SET 
Table 14. Stage 2 Protein Descriptive Statistics (nanograms/mL) 
 Combined  CAD  Normal 














VCAM (ng) 120  71 1425.6 435.1 1073.3 1415.7 1658.0  49 1250.6 602.9 906.7 1106.8 1388.0 
MPO (ng) 120  71 950.2 710.7 397.4 816.8 1155.3  49 676.7 420.5 390.1 629.3 838.5 
OPN (ng) 120  71 23.0 20.3 9.4 17.3 29.1  49 17.6 14.1 7.3 13.6 23.5 
Resistin (ng) 120  71 123.3 87.7 55.3 97.7 167.7  49 102.8 62.6 64.3 82.3 127.8 
MMP7 (ng) 120  71 4.9 2.3 3.1 4.6 6.0  49 4.8 3.7 3.3 4.3 4.8 
 
Table 15. Stage 2 Protein Descriptive Statistics (micrograms/mL) 
 Combined  CAD  Normal 














Fibrinogen (μg) 120  71 37.7 111.6 6.3 9.4 20.0  101 4.1 6.3 1.8 3.2 5.6 
Acrp30 (μg) 120  71 5.9 4.8 3.3 4.5 6.6  101 5.3 3.8 3.0 4.8 7.7 
CRP (μg) 120  71 3.6 7.2 0.6 1.1 3.0  101 0.3 0.6 0.1 0.3 0.8 





Table 16. Stage 1 Protein Descriptive Statistics (picograms/mL) 
 Combined  CAD  Normal 














IFNγ (pg) 120  71 5.6 13.2 0.95 3.0 4.7  49 2.8 3.2 0.8 2.0 3.9 












2. GRAPHS OF ODDS RATIOS BY QUARTILE FROM UNIVARIATE LOGISTIC 
REGRESSION 
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3. MULTIVARIATE LOGISTIC REGRESSION MODEL INVOLVING CLINICAL 
CHARACTERISTICS AND FACTORIED PROTEINS (BY QUARTILE) 










Intercept -5.39 1.01 <.0001 -- -- 
OPN      
2 1.29 0.54 0.0167 3.62 1.26 to 10.41 
3 1.98 0.55 0.0003 7.24 2.45 to 21.41 
4 4.83 0.83 <.0001 125.39 24.71 to 636.16 
IL1β      
2 0.80 0.56 0.156 2.22 0.74 to 6.74 
3 1.60 0.57 0.0053 4.95 1.61 to 15.21 
4 2.58 0.63 <.0001 13.24 3.82 to 45.22 
Fibrinogen      
2 0.86 0.53 0.1058 2.37 0.83 to 6.77 
3 1.52 0.58 0.0082 4.59 1.48 to 14.23 
4 1.40 0.60 0.0199 4.07 1.25 to 13.26 
Apo-B100      
2 0.11 0.80 0.8931 1.11 0.23 to 5.37 
3 1.66 0.82 0.0413 5.28 1.07 to 26.09 
4 1.91 0.79 0.0151 6.75 1.45 to 31.46 
Diabetes 1.24 0.46 0.0072 3.46 1.40 to 8.57 
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